Why Orion Oyj (HLSE:ORNBV) Is Back In The Spotlight

Orion Oyj’s new immuno-oncology moves

Orion Oyj (HLSE:ORNBV) is back in focus after two closely timed cancer medicine updates. The group has secured European rights to a pembrolizumab biosimilar and advanced its first immuno-oncology biologic into human trials.

Against this backdrop, Orion Oyj’s share price sits at €81.35, with a 90-day share price return of 15.06% and a year to date share price return of 28.52%, while the 3-year total shareholder return of 127.35% points to momentum that these immuno oncology updates may be reinforcing.

Spot opportunities riding similar oncology and healthcare momentum by scanning our hand picked 126 healthcare AI stocks alongside Orion Oyj.

After Orion Oyj’s oncology headlines and strong recent share gains, the puzzle now is whether that momentum already sits in the €81.35 price or still leaves room that patient buyers might prefer.

Most Popular Narrative: 6% Overvalued

The most followed narrative now places Orion Oyj’s fair value at €76.67, slightly below the €81.35 last close, which implies a modest premium built into the current price.

The analysts have a consensus price target of €76.67 for Orion Oyj based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €86.0, and the most bearish reporting a price target of just €55.0.

See why 6 investors see Orion Oyj as 6% overvalued.

Result: Fair Value of €76.67 (OVERVALUED)

Still, Orion Oyj’s story could change quickly if Nubeqa milestones land sooner than expected or if the oncology pipeline produces stronger than modeled trial results.

Find out about the key risks to this Orion Oyj narrative.

Another View on Orion Oyj’s Valuation

Analysts calling Orion Oyj about 6% overvalued are leaning on their earnings forecasts and a target P/E of 17.3x. Our DCF model points in the opposite direction, with the shares trading around €81.35 versus an estimated future cash flow value of €159.18, which screens as materially undervalued. Which story do you trust more: the headline multiple or the cash flows underneath it?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If this mix of optimism and caution around Orion Oyj leaves you on the fence, move quickly to review the underlying numbers yourself and stress test the bullish angles. Then judge how those positives stack up by checking the 3 key rewards.

Looking for more Orion Oyj style investment ideas?

If Orion Oyj has your attention, do not stop with a single ticker. Use the Simply Wall Street Screener to line up your next potential opportunities.

• Target potential mispricings by scanning a curated pool of companies flagged as promising on value and quality through the 185 high quality undervalued stocks.
• Strengthen your income stream by focusing on businesses screened for robust payouts using the 164 dividend fortresses.
• Sleep easier by reviewing a 227 resilient stocks with low risk scores that filters for resilient balance sheets and lower risk scores before market sentiment shifts past you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com